VRML Vermillion

Vermillion to Report Second Quarter 2019 Financial Results on August 8

Vermillion to Report Second Quarter 2019 Financial Results on August 8

AUSTIN, Texas, July 31, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the three and six months ended June 30, 2019 on Thursday, August 8, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Thursday, August 8th @ 4:30pm Eastern Time

Domestic:

International:

Conference ID:

Webcast:
855-327-6837

631-891-4304

10007441



About Vermillion, Inc.

Vermillion, Inc. is dedicated to the discovery; development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use.

Visit or more information.

Investor Relations Contact:

Ashley R. Robinson

LifeSci Advisors, LLC

Tel 617-535-7742

EN
31/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vermillion

 PRESS RELEASE

Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare ...

Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare Conference AUSTIN, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the 2020 Cantor Virtual Healthcare Conference taking place on September 15-17, 2020. Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer will be available for 1x1 meetings with investors on September 17, 2020.  Conference details are as follows:   Cantor Virtual Healthcare Confe...

 PRESS RELEASE

UPDATE – Aspira Women’s Health Reports Second Quarter 2020 Financi...

UPDATE – Aspira Women’s Health Reports Second Quarter 2020 Financial Results Conference Call scheduled for today, August 13th at 4:30 p.m. ET AUSTIN, Texas, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020. “Despite late first quarter and second quarter challenges from COVID-19, we have delivered strong revenue and volume growth in the first half of 2020 as compared to the first half of 2019. ...

 PRESS RELEASE

Aspira Women’s Health Reports Second Quarter 2020 Financial Results

Aspira Women’s Health Reports Second Quarter 2020 Financial Results Conference Call scheduled for today, August 13th at 4:30 p.m. ET AUSTIN, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020. “Despite late first quarter and second quarter challenges from COVID-19, we have delivered strong revenue and volume growth in the first half of 2020 as compared to the first half of 2019. In fact, ...

 PRESS RELEASE

Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial ...

Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial Results on August 13th AUSTIN, Texas, July 31, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Thursday, August 13th @ 4:30pm ETDomestic:201-689-8472International:877-407-4021Conference ID:13706942Webcast: About Aspira Women’s Health Inc...

 PRESS RELEASE

Aspira Women’s Health Inc. Announces Equity Financing of Approximate...

Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million AUSTIN, Texas, July 01, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have agreed to purchase approximately $11 million of unregistered shares of ASPIRA's common stock in a private placement at a price of $3.50 per share. The closing of the private placement is expected to occur on July 6...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch